Author: Healio ophthalmology

Alimera, pSivida amend licensing agreement

Alimera Sciences may now seek approval of Iluvien for the secondary indication of posterior uveitis in the European Union, Middle East and Africa, according to a press release from the company.Alimera and pSivida amended a previous agreement, under which “Alimera held the worldwide license from pSivida to sell Iluvien for the treatment of all ocular diseases other than uveitis,” the release said.

Air descemetopexy may treat Descemet’s membrane detachment after cataract surgery

Air descemetopexy can treat Descemet’s membrane detachment after cataract surgery, avoiding the need for endothelial transplantation in many cases, according to a study. At Aravind Eye Hospital in Pondicherry, India, air descemetopexy was performed in 112 patients between January 2013 and December 2015, out of 119,031 cataract surgery interventions. One hundred ten patients had at least 1 month of follow-up and were included in the analysis.

Johnson & Johnson CEO discusses future of health care

Health care in the United States will need continued innovation and a commitment to improvement from legislators and industry alike for a sustainable future, Alan Gorsky, CEO of Johnson & Johnson, said at the OCTANe Ophthalmology Technology Summit. Gorsky discussed the country’s changing health care landscape in an interview with Jim Mazzo, global president of ophthalmic devices at Carl Zeiss Meditec, during the meeting in Newport Beach, California, in June. He focused on how industry leaders and legislators in Washington need to work together to improve the Affordable Care Act (Read more...)

Lower doses of atropine yield less rebound

Whereas level I evidence supports the use of topical atropine to prevent myopic progression of up to 1 D per year in pediatric patients, higher doses have been shown to increase rates of myopic rebound, according to an American Academy of Ophthalmology report.Researchers reviewed 17 level I, II and III studies of children with myopia who had been treated with atropine ophthalmic solution of varying concentrations – 1%, 0.5%, 0.1% and 0.01% – to prevent myopia progression.

Man experiences painless vision loss after combined DSAEK, cataract surgery

A 65-year-old Caucasian man was emergently referred to the retina department at the New England Eye Center for less than 24 hours of painless loss of vision in the right eye. He had undergone a combined Descemet’s stripping automated endothelial keratoplasty and cataract extraction in the right eye 6 days before presentation. His immediate postoperative period had been uncomplicated thus far.The day of presentation, he returned to his surgeon’s office and was immediately referred to our retina department with concern for endophthalmitis. He had no other complaints. He had been (Read more...)

Biomimetic 3-D printed corneas may revolutionize corneal transplantation

A biomimetic cornea that combines stem cell technology and 3-D printing may be the future of corneal transplantation.“Research is still at the early stages, but what the future may bring is a customized graft, perfectly tailored for the patient, derived from the patient’s own cells, with no risk of rejection. A concept that is entirely different from the types of artificial corneas we have now, and also a potential solution to the cornea transplant tissue shortage that is currently a global concern,” Nadia Zakaria, MD, PhD, said.